This bill amends Florida's controlled substances laws by adding 7-Hydroxymitragynine and xylazine to the list of Schedule I controlled substances, which are recognized for their high potential for abuse and lack of accepted medical use. It also provides an exception for FDA-approved xylazine animal drug products used according to their approved applications. The legislation introduces new criminal penalties for the sale, manufacture, or delivery of xylazine, including mandatory minimum sentences for trafficking based on the quantity involved, with penalties ranging from 3 years and a $100,000 fine for 28 to less than 100 grams, to a minimum of 25 years and a $500,000 fine for 200 grams or more. The effective date for these changes is set for July 1, 2026, with some provisions taking effect on October 1, 2026.

Additionally, the bill expands the list of controlled substances to include various synthetic cannabinoids and related compounds, addressing the evolving nature of synthetic drugs. It emphasizes the need for a broad definition of synthetic cannabinoids to encompass various structural analogs, isomers, and derivatives, while also highlighting the lack of standardized nomenclature that complicates enforcement. By regulating these substances, the bill aims to enhance public safety and provide law enforcement with the necessary tools to combat the growing issue of synthetic drug use and trafficking.

Statutes affected:
S 432 Filed: 893.13, 893.135